Distinct Effects of Methamphetamine Isomers on Limbic Norepinephrine and Dopamine Transmission in the Rat Brain. 2023

Ryan C Pauly, and Rohan V Bhimani, and Jun-Xu Li, and Bruce E Blough, and Antonio Landavazo, and Jinwoo Park

Methamphetamine (METH) is a psychostimulant that primarily exerts its effects on the catecholamine (dopamine (DA) and norepinephrine (NE)) systems, which are implicated in drug addiction. METH exists as two distinct enantiomers, dextrorotatory (d) and levorotatory (l). In contrast to d-METH, the major component of illicit METH used to induce states of euphoria and alertness, l-METH is available without prescription as a nasal decongestant and has been highlighted as a potential agonist replacement therapy to treat stimulant use disorder. However, little is known regarding l-METH's effects on central catecholamine transmission and behavior. In this study, we used fast-scan cyclic voltammetry to elucidate how METH isomers impact NE and DA transmission in two limbic structures, the ventral bed nucleus of the stria terminalis (vBNST) and nucleus accumbens (NAc), respectively, of anesthetized rats. In addition, the dose-dependent effects of METH isomers on locomotion were characterized. d-METH (0.5, 2.0, 5.0 mg/kg) enhanced both electrically evoked vBNST-NE and NAc-DA concentrations and locomotion. Alternatively, l-METH increased electrically evoked NE concentration with minimal effects on DA regulation (release and clearance) and locomotion at lower doses (0.5 and 2.0 mg/kg). Furthermore, a high dose (5.0 mg/kg) of d-METH but not l-METH elevated baseline NE and DA concentrations. These results suggest mechanistic differences between NE and DA regulation by the METH isomers. Moreover, l-METH's asymmetric regulation of NE relative to DA may have distinct implications in behaviors and addiction, which will set the neurochemical framework for future studies examining l-METH as a potential treatment for stimulant use disorders.

UI MeSH Term Description Entries

Related Publications

Ryan C Pauly, and Rohan V Bhimani, and Jun-Xu Li, and Bruce E Blough, and Antonio Landavazo, and Jinwoo Park
September 1985, Life sciences,
Ryan C Pauly, and Rohan V Bhimani, and Jun-Xu Li, and Bruce E Blough, and Antonio Landavazo, and Jinwoo Park
May 1976, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
Ryan C Pauly, and Rohan V Bhimani, and Jun-Xu Li, and Bruce E Blough, and Antonio Landavazo, and Jinwoo Park
August 2021, Journal of neurochemistry,
Ryan C Pauly, and Rohan V Bhimani, and Jun-Xu Li, and Bruce E Blough, and Antonio Landavazo, and Jinwoo Park
October 1974, Brain research,
Ryan C Pauly, and Rohan V Bhimani, and Jun-Xu Li, and Bruce E Blough, and Antonio Landavazo, and Jinwoo Park
January 1980, Psychopharmacology,
Ryan C Pauly, and Rohan V Bhimani, and Jun-Xu Li, and Bruce E Blough, and Antonio Landavazo, and Jinwoo Park
July 1976, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
Ryan C Pauly, and Rohan V Bhimani, and Jun-Xu Li, and Bruce E Blough, and Antonio Landavazo, and Jinwoo Park
August 1990, Biochemical pharmacology,
Ryan C Pauly, and Rohan V Bhimani, and Jun-Xu Li, and Bruce E Blough, and Antonio Landavazo, and Jinwoo Park
September 1986, Bulletin of environmental contamination and toxicology,
Ryan C Pauly, and Rohan V Bhimani, and Jun-Xu Li, and Bruce E Blough, and Antonio Landavazo, and Jinwoo Park
May 1994, Biochemical pharmacology,
Ryan C Pauly, and Rohan V Bhimani, and Jun-Xu Li, and Bruce E Blough, and Antonio Landavazo, and Jinwoo Park
July 2019, Neuroscience and biobehavioral reviews,
Copied contents to your clipboard!